Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) will release third quarter 2025 financial results for the period ended September 30, 2025 before market open on Monday, November 10, 2025. The company will hold its inaugural earnings conference call the same day at 8:30 a.m. Eastern Time to discuss results and answer analyst questions.
Dial-in details: 1-844-425-9470 (U.S.) and 201-298-0878 (international). A live webcast will be available on the PRE conference call page and an audio replay will be posted on the investor relations website at https://ir.prenetics.com/.
Prenetics (Nasdaq: PRE) announced that its IM8 brand achieved a record $9.0 million in revenue for October 2025, representing 32% month-over-month growth from September's $6.8 million, and reached approximately $108 million in annualized recurring revenue (ARR) 11 months after launch.
Other disclosed metrics: an all-time single-day revenue record of $400,000, average order value rising from ~$110 to $145, 13 million servings delivered to over 420,000 customers across 31 countries, and 80% of new orders via subscription. Prenetics completed a $44 million equity offering to fund global expansion and projects a minimum of $10 million monthly revenue by December 2025, ~$60 million in IM8 revenue for FY2025, and $180–200 million for FY2026.
Prenetics (NASDAQ: PRE) acquired 100 Bitcoin at an average price of $109,594 per BTC, increasing its treasury to 378 BTC (valued at ~$46 million). The purchase was funded as the initial deployment of proceeds from a completed $44 million equity offering that closed on October 28, 2025.
Following the acquisition and financing, Prenetics reports approximately $127 million in total liquidity ($86 million cash and $41 million in Bitcoin) and zero debt. The company also says its IM8 supplement brand reached $100 million ARR within 11 months, with 420,000 customers, ~80% subscription reorder rate, and FY2026 IM8 revenue guidance of $180–$200 million.
Prenetics (NASDAQ: PRE) published a 32-page manifesto titled “The Dual-Engine Revolution” by CEO Danny Yeung outlining a strategy that pairs rapid healthcare growth with a disciplined Bitcoin treasury approach.
Key facts: IM8 reached $100M ARR in 11 months and projects $180–$200M revenue for FY2026. The company holds 277 BTC and adds 1 BTC daily via a stated accumulation strategy. The manifesto is available in multiple formats and links to investor resources and real-time BTC holdings.
Prenetics (NASDAQ: PRE) closed a best-efforts public offering on Oct 28, 2025, selling 2,722,642 Class A ordinary shares and associated Class A and Class B common warrants at a combined price of $16.08 per share with warrants. Gross proceeds were approximately $44.0 million before fees, down from ~$48.0 million previously announced. The Class A warrants carry a $24.12 exercise price (50% premium) and Class B warrants a $32.16 exercise price (100% premium); both are immediately exercisable for five years. The company said proceeds will fund the global expansion of IM8 and strategic accumulation of Bitcoin (BTC). Dominari Securities acted as sole placement agent.
Prenetics (NASDAQ: PRE) priced a public offering to raise approximately $48 million in gross proceeds, plus up to $168 million more if attached Class A and Class B warrants are fully exercised, potentially totaling $216 million. The offering includes double warrants exercisable at $24.12 (50% premium) and $32.16 (100% premium), each expiring in five years.
Company highlights IM8's rapid traction: $100M ARR in 11 months, October run-rate ~$103M ARR, and 2026 guidance $160–200M. Post-offering liquidity expected at ~$100M cash plus 275 BTC (~$31M), totaling ~$131M.
Prenetics (NASDAQ: PRE) priced a best-efforts public offering to sell 2,992,596 Class A ordinary shares (or pre-funded warrants) together with associated Class A and Class B common warrants at a combined offering price of $16.08 per unit, for expected gross proceeds of approximately $48.0 million before fees and expenses. The Class A warrants carry a $24.12 exercise price and Class B warrants a $32.16 exercise price; each warrant is immediately exercisable and expires five years after issuance.
Proceeds are intended to fund the global expansion of IM8 and the company’s strategic accumulation of Bitcoin (BTC). The offering is expected to close on October 28, 2025, subject to customary closing conditions, with Dominari Securities as placement agent.
Prenetics Global (NASDAQ:PRE) announced on Oct 25, 2025 that it has commenced a public offering of Class A ordinary shares (or prefunded warrants) and common warrants (the "Offering").
The company said net proceeds are intended to fund the global expansion of IM8 and the strategic accumulation of Bitcoin (BTC) as part of a dual health-and-wealth strategy. The Offering is being made from an effective Form F-3 shelf registration declared effective by the SEC on Sept 11, 2025, and is subject to market conditions with no assurance as to completion, size, or terms.
Dominari Securities is acting as sole placement agent; a preliminary prospectus supplement and shelf prospectus will be filed with the SEC and made available to investors.
Prenetics (NASDAQ: PRE) announced on October 8, 2025 the launch of Daily Ultimate Longevity under its IM8 brand. The powder formulation is described as the first supplement to target all 12 hallmarks of aging using a five-complex system with specified clinical ingredient doses (e.g., 3,000 mg glycine, 300 mg NMN, 3 mg spermidine).
IM8 reported rapid scaling from approximately $600k monthly at launch to $6.6M monthly revenue in September 2025 and cites a 2,457% CAGR, targeting $100M ARR within its first year. Product pricing is $149 one-time or $119/month subscription. Prenetics reports >$90M liquid assets (≈$60M cash and 255.4 BTC ≈$31.6M) and says it is debt-free with a path to profitability in early 2026.
Prenetics (NASDAQ: PRE) completed the divestment of ACT for $72 million, receiving $39.9 million in cash upfront and an additional $6.3 million held in escrow payable over 18 months, bringing total transaction proceeds to $46 million. The company says this lifts cash reserves to over $60 million (excluding Bitcoin) and leaves Prenetics debt-free. Prenetics is reallocating resources to its consumer health brand IM8, which is on pace to reach an $100 million ARR within its first 12 months. The company also reports a Bitcoin treasury of 255.4 BTC valued at $31.6 million (investment cost $27.8 million), an unrealized profit of $3.86 million (13.9% return), and a 1 BTC/day purchase policy since August 1, 2025.